KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $13.8 million.

  • Alnylam Pharmaceuticals' Depreciation & Amortization (CF) fell 128.02% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 60.02%. This contributed to the annual value of $56.7 million for FY2024, which is 483.96% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Depreciation & Amortization (CF) is $13.8 million, which was down 128.02% from $13.9 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $15.0 million during Q2 2024, and its lowest value of $9.5 million during Q1 2022.
  • Its 5-year average for Depreciation & Amortization (CF) is $12.9 million, with a median of $13.5 million in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 6551.95% in 2021, then crashed by 2492.66% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Depreciation & Amortization (CF) stood at $11.4 million in 2021, then grew by 25.81% to $14.3 million in 2022, then dropped by 5.79% to $13.5 million in 2023, then rose by 5.09% to $14.2 million in 2024, then fell by 2.58% to $13.8 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $13.8 million for Q3 2025, versus $13.9 million for Q2 2025 and $14.4 million for Q1 2025.